Juniper Pharmaceuticals is developing therapeutics that address unmet medical needs in women’s health. The Company's current pipeline leverages the 505(b)(2) regulatory pathway with new formulations of existing pharmaceuticals. Juniper's current intravaginal ring product candidates are JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women; JNP-0201, a combination estrogen + progesterone IVR for menopausal symptoms; and, JNP-0301, a progesterone IVR for the prevention of preterm birth in women with a short cervical length at mid-pregnancy.

Type
Public
HQ
Boston, US
Founded
1986
Size (employees)
139 (est)
Juniper Pharmaceuticals was founded in 1986 and is headquartered in Boston, US
Report incorrect company information

Juniper Pharmaceuticals Office Locations

Juniper Pharmaceuticals has an office in Boston
Boston, US (HQ)
33 Arch St
Show all (1)
Report incorrect company information

Juniper Pharmaceuticals Financials and Metrics

Juniper Pharmaceuticals Financials

Juniper Pharmaceuticals's revenue was reported to be $49.98 m in FY, 2017
USD

Revenue (FY, 2017)

50 m

Gross profit (FY, 2017)

21 m

Gross profit margin (FY, 2017), %

42.1%

Net income (FY, 2017)

(2.1 m)

EBIT (FY, 2017)

(3.9 m)

Market capitalization (20-Apr-2018)

98 m

Cash (31-Dec-2017)

21.4 m

EV

80.3 m
Juniper Pharmaceuticals's current market capitalization is $98 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

29.2 m32.5 m37.6 m54.6 m50 m

Revenue growth, %

11%16%45%

Cost of goods sold

13.3 m17.7 m21.4 m24.3 m29 m

Gross profit

16 m14.8 m16.1 m30.3 m21 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

7.1 m7.2 m6.9 m11.5 m8.3 m10.2 b11.5 b12.1 m11.9 m11.6 m11.2 b14 b

Cost of goods sold

3.2 m4.3 m3.9 m5.1 m4.9 m5.6 b6.4 b6.4 m6.5 m5.7 m6.6 b7.7 b

Gross profit

3.9 m3 m3 m6.4 m3.4 m4.6 b5 b5.8 m5.4 m5.9 m4.7 b6.3 b

Gross profit Margin, %

55%41%44%56%41%45%44%48%46%51%42%45%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

20.7 m16.8 m13.9 m21 m21.4 m

Accounts Receivable

7.2 m5.3 m181 k

Inventories

2.6 m3.2 m3.6 m5.6 m6.3 m

Current Assets

32.2 m26.4 m26.7 m34.7 m36 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

18.8 m12.2 m11.8 m16.4 m16.3 m16.1 m17.4 m13.5 m13 m15 m21.8 m21.5 m

Accounts Receivable

6.8 m7.3 m7.2 m5.3 m4.8 m6.5 m7.9 m8 m6.2 m5.3 m4.5 m6.9 m

Inventories

2 m2.4 m3.6 m2.9 m3.3 m3.8 m3.1 m3.2 m3.9 m4.8 m5.7 m5.2 m

Current Assets

31.4 m23.2 m24 m25.8 m26.1 m28.6 m30.7 m27.5 m26.4 m26.4 m33.5 m35.4 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

6.7 m3.4 m(2.1 m)6 m(2.1 m)

Depreciation and Amortization

919.1 k2 m1.9 m1.9 m2.3 m

Inventories

46.5 k(619 k)(424 k)(2 m)(704 k)

Accounts Payable

314.8 k91 k(925 k)1.6 m183 k
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

744.2 k429 k622 k4.3 m(692 k)(1 m)(65 k)362 k(1.7 m)248 k(1.4 b)

Depreciation and Amortization

376.5 k448 k949 k1.5 m523 k1 m1.5 m

Inventories

635.4 k178 k(966 k)(273 k)(130 k)(579 k)94 k3.2 m3.9 m4.8 m5.7 m

Accounts Payable

95.5 k373 k282 k(1.7 m)(343 k)(37 k)532 k3.8 m3.8 m4.8 m2.7 m
USDY, 2017

EV/EBIT

-20.8 x

EV/CFO

37.8 x

Revenue/Employee

359.6 k

Financial Leverage

1.5 x
Show all financial metrics

Juniper Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

4
Show all operating metrics
Report incorrect company information

Juniper Pharmaceuticals News and Updates

Report incorrect company information